Corcept Therapeutics Incorporated (NASDAQ: CORT) insider Sean Maduck sells 25,000 shares
Corcept Therapeutics Incorporated (NASDAQ: CORT) insider Sean Maduck sold 25,000 shares of the company in a transaction dated Wednesday, July 7. The shares were sold at an average price of $ 22.19, for a total trade of $ 554,750.00. The transaction has been disclosed in a legal file with the Securities & Exchange Commission, which can be accessed via the SEC website.
Actions of NASDAQ: CORT traded up $ 0.21 during the Friday midday session, reaching $ 22.04. The company had a trading volume of 203,462 shares, compared to an average volume of 576,020. Corcept Therapeutics Incorporated has a one-year low at $ 12.20 and a one-year high at $ 31.18. The company has a market cap of $ 2.57 billion, a price-to-earnings ratio of 27.99, a price-to-earnings-growth ratio of 2.43, and a beta of 0.72. The company has a fifty-day simple moving average of $ 21.80.
Corcept Therapeutics (NASDAQ: CORT) last released its quarterly results on Thursday, May 6. The biotech company reported earnings per share of $ 0.18 for the quarter, missing Zacks’ consensus estimate of $ 0.21 ($ 0.03). Corcept Therapeutics generated a net margin of 29.23% and a return on equity of 20.11%. The company posted revenue of $ 79.44 million in the quarter, compared to analysts’ estimates of $ 96.99 million. In the same quarter of last year, the company made EPS of $ 0.34. The company’s revenue for the quarter was down 14.8% from the same quarter last year. Sell-side analysts expect Corcept Therapeutics Incorporated to post earnings per share of 0.8 for the current year.
Large investors have recently increased or reduced their holdings in the stock. Janus Henderson Group PLC strengthened its position in Corcept Therapeutics shares by 17.5% in the 4th quarter. Janus Henderson Group PLC now owns 140,665 shares of the biotech company valued at $ 3,680,000 after purchasing an additional 20,928 shares during the period. Squarepoint Ops LLC acquired a new stake in Corcept Therapeutics during the 4th quarter for a value of approximately $ 1,660,000. Boston Trust Walden Corp strengthened its position in Corcept Therapeutics by 88.0% during the 1st quarter. Boston Trust Walden Corp now owns 770,565 shares of the biotech company valued at $ 18,332,000 after acquiring an additional 360,721 shares during the period. Parallel Advisors LLC strengthened its position in Corcept Therapeutics by 1.0% in the 1st quarter. Parallel Advisors LLC now owns 1,563,974 shares of the biotech company valued at $ 37,207,000 after acquiring an additional 15,358 shares during the period. Finally, Principal Financial Group Inc. strengthened its position in Corcept Therapeutics by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 746,416 shares of the biotech company valued at $ 17,757,000 after acquiring 2,400 additional shares during the period. Institutional investors and hedge funds hold 69.06% of the company’s shares.
Several research firms recently commented on CORT. HC Wainwright reduced its target price on Corcept Therapeutics from $ 32.00 to $ 29.00 and set a “buy” note for the company in a research note on Wednesday, June 23. The UBS Group reaffirmed a “positive” rating on the shares of Corcept Therapeutics in a research report on Tuesday 22 June. Zacks investment research downgraded Corcept Therapeutics from a “sell” rating to a “conservation” rating and set a target price of $ 24.00 on the stock in a report released Wednesday. Finally, TheStreet downgraded Corcept Therapeutics from a “b” rating to a “c +” rating in a report released on Wednesday, June 2. Two analysts rated the stock with a conservation rating and two gave the company’s stock a buy rating. The stock currently has an average rating of “Buy” and a consensus target price of $ 23.00.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated discovers, develops and markets drugs for the treatment of serious metabolic, oncological and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes or intolerance glucose, and who have failed surgery or surgery.
See also: Liquidity
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: What are the advantages of a growth and income fund?
7 cyclical stocks that can help you play defense
A cyclical stock is a stock that produces returns influenced by macroeconomic or systematic changes in the economy at large. In strong economic times, these stocks tend to show strong growth as they are influenced by discretionary consumer spending. Of course, this means that the opposite is also true. When the economy is weak, these stocks may retreat more than other stocks.
Cyclical stocks span many sectors, but travel and entertainment stocks spring to mind. Airlines, hotels and restaurants are all examples of cyclical industries that do well in times of economic growth, but are among the first to fall back in times of recession.
Why do cyclical stocks deserve a place in an investor’s portfolio? Believe it or not, this is for the relative predictability they offer. Investors may like to speculate in growth stocks, but these are prone to bubbles. That’s not to say that cyclical stocks aren’t volatile, but they do offer a bit more predictable price movement.
In this special presentation, we take a look at cyclical stocks that look strong emerging from the pandemic. And some of those stocks have held up well during the pandemic, which means they’re starting from a more solid base.
Check out the “7 Cyclical Actions That Can Help You Play Defense.”